Latest Headlines

  1. RoosterBio Announces Collaboration With Thermo Fisher Scientific To Advance Cell And Exosome Therapy Manufacturing 4/29/2025

    RoosterBio, Inc., a leading supplier of adult human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, today announced a new collaboration with Thermo Fisher Scientific, the world leader in serving science.

  2. Avance Clinical To Showcase Asia-Pacific Clinical Trial Expertise At BIO Korea 2025 4/15/2025

    Avance Clinical, a leading full-service global Contract Research Organization (CRO) specializing in high-quality, agile clinical biotech research services, will attend BIO Korea 2025 to meet with biotechs and share clinical trial capabilities across the region including Australia, New Zealand, South Korea, Taiwan, North America and beyond.

  3. Nikon CeLL Innovation Enters Into A Strategic License Agreement With RoosterBio 4/15/2025

    Nikon CeLL innovation Co., Ltd. (NCLi), a subsidiary of Nikon Corporation has entered into a strategic licensing agreement with RoosterBio, Inc. (RoosterBio), a leading stem cell technology company in the US.

  4. Novotech Expands South Korean Presence With New Hospital Trial Site Deal 4/4/2025

    Australian CRO Novotech has signed a memorandum of understanding with the Kyungpook National University Hospital (KNUH), furthering its partnership strategy in South Korea.

  5. Novotech Named Best Contract Research Organization In Australia At Asia-Pacific Biopharma Excellence Awards 2025 4/3/2025

    Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company that provides biotech and small- to mid-sized pharma companies an accelerated path to market has been recognized as the Best Contract Research Organization in Australia at the Asia-Pacific Biopharma Excellence Awards (ABEA) 2025. 

  6. Novotech Report Reveals Growth In siRNA Research 4/3/2025

    Sydney, March 2025 – Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, has released its newest preclinical report exploring the evolving landscape of small interfering RNA (siRNA) therapeutics. This report provides insights for biotech and pharmaceutical companies leveraging RNA-based precision medicine to develop next-generation treatments for oncology, metabolic disorders, and rare genetic diseases. 

  7. Landmark Bio Acquired By Artis BioSolutions To Expand Manufacturing And Commercialization Of Advanced Therapies 4/2/2025
  8. Miltenyi Biotec To Commercially Supply CliniMACS® Platform To Autolus Therapeutics For Its Manufacture Of FDA-Approved AUCATZYL® (Obecabtagene Autoleucel – Obe-Cel) 3/28/2025

    Miltenyi Biotec, a global leader innovating technologies and services for patient-specific cell and gene therapies, today announced that it will supply Miltenyi Biotec’s CliniMACS Prodigy® instruments, reagents, and disposables for the manufacture of Autolus’ FDA-approved AUCATZYL® (obecabtagene autoleucel), as part of its longstanding partnership with the CAR T cell therapy developer since 2018.

  9. Global Reach For Biotechs: Avance Clinical Secures MOUs With Four Premier Taiwanese Trial Sites 3/24/2025

    Avance Clinical, a leading full-service global Contract Research Organization (CRO) specializing in high-quality, agile clinical biotech research services, is pleased to announce the signing of four Memorandums of Understanding (MOUs) with key clinical trial sites in Taiwan this week.

  10. Avance Clinical Expands In Asia With Taipei Office To Accelerate Biotech Clinical Trials 3/24/2025

    Avance Clinical, the award-winning, full-service Contract Research Organization (CRO) specializing in delivering agile and accelerated clinical development solutions for global biotechs, has further strengthened its presence in Asia with the opening of an office in Taipei, Taiwan.